

Denis Xavier

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6137578/denis-xavier-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

10
papers

1,238
citations

7
h-index

10
g-index

10
ext. papers

1,567
ext. citations

21.5
avg, IF

3.03
L-index

#	Paper	IF	Citations
10	Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016 , 374, 2021-31	59.2	440
9	Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016 , 374, 2009-20	59.2	382
8	Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016 , 374, 2032-43	59.2	199
7	The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. <i>Circulation</i> , 2010 , 122, 2078-88	16.7	120
6	Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges. <i>European Heart Journal</i> , 2014 , 35, 353-64	9.5	57
5	Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and ParticipantsgBaseline Characteristics. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 311-8	3.8	21
4	The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct. <i>American Heart Journal</i> , 2018 , 206, 72-79	4.9	12
3	Behavioural risk factors distribution of cardiovascular diseases and its association with normotension, prehypertension and hypertension amongst tea garden population in Dibrugarh district of Assam. <i>Clinical Epidemiology and Global Health</i> , 2016 , 4, 45-50	1.8	3
2	Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants. <i>European Heart Journal</i> , 2021 , 42, 2995-3007	9.5	3
1	Polypharmacotherapy for primary prevention of cardiovascular disease. <i>Indian Heart Journal</i> , 2008 , 60, B29-33	1.6	1